Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Survivors of Childhood Cancers Living Longer Due to Improvements in Care and Follow-up

May 31st 2015

Over the past 30 years, survivors of childhood cancers have become less likely to die of illnesses caused by their treatment, such as new malignancies or cardiac or lung disease.

Dr. Chanan-Khan on Ibruitinib Combined with BR in CLL/SLL

May 30th 2015

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Cancer Center, Mayo Clinic, discusses a recent study that examined ibrutinib combined with bendamustine and ritxuimab (BR) in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Ibrutinib Regimen Improves PFS by 80% in Phase III CLL Study

May 30th 2015

Adding ibrutinib to standard bendamustine and rituximab (BR) reduced the risk of disease progression by 80% compared with BR plus placebo in patients with pretreated CLL or SLL.

Deletion 20q in CLL May Represent Disease Progression

May 28th 2015

The identification of a deletion 20q in a patient with chronic lymphocytic leukemia may not indicate they have developed a myelodysplastic syndrome as was previously assumed.

Dr. Wierda on Ibrutinib Resistance in CLL

May 26th 2015

William G. Wierda, MD, PhD, medical director, Leukemia Center, The University of Texas MD Anderson Cancer Center, discusses resistance to ibrutinib in patients with chronic lymphocytic leukemia (CLL).

CTCs Show Promise as Biomarker for Recurrence in DLBCL

May 21st 2015

Patients with diffuse large B-cell lymphoma who developed detectable circulating tumor DNA during surveillance were more than 200 times more likely to have their disease progress than those who did not have detectable ctDNA.

Radford Discusses Future of Novel Therapies in Non-Hodgkin Lymphoma

May 12th 2015

In an interview with OncLive, John Radford, MD, discusses the impact of novel agents in non-Hodgkin lymphoma and what continued research is necessary to overcome treatment challenges.

Dr. Garcia-Manero on Deferasirox in Iron Chelation Therapy for MDS

May 7th 2015

Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses deferasirox (Exjade) in iron chelation therapy for patients with myelodysplastic syndromes (MDS).

Dr. Townsley on Screening for GATA2 in At-Risk Patients for MDS, AA, and AML

May 6th 2015

Danielle Townsley, MD, staff clinician, Cell Biology Section, National Institutes of Health, discusses a study which examined screening for GATA2 in patients who are at risk for myelodysplastic syndromes (MDS), aplastic anemia (AA), and acute myeloid leukemia (AML).

Somatic Mutations Could Predict Response to Hypomethylating Agents in MDS

May 2nd 2015

A biomarker model that incorporates the mutational status of multiple somatic genes could be used to predict response to hypomethylating agents for patients with myelodysplastic syndromes.

IPSS Risk and EPO Levels Predict Response to ESAs in MDS

May 2nd 2015

Serum erythropoietin levels and risk by IPSS were predictive of response to erythropoiesis-stimulating agents in patients with myelodysplastic syndromes.

Dr. Gail Roboz on Molecular Mutations in MDS

May 2nd 2015

Gail J. Roboz, MD, associate professor of Medicine, director, Leukemia Program, Weill Medical College of Cornell University, New York-Presbyterian Hospital, discusses the growing field of molecular mutations in myelodysplastic syndromes (MDS).

Dr. Zeidan on Subsequent MDS in Prostate Cancer Patients After Radiotherapy

May 2nd 2015

Amer Zeidan, MBBS, MHS, assistant professor of Medicine, Hematology, Yale Cancer Center, discusses a population-based study of subsequent myelodysplastic syndromes (MDS) in prostate cancer patients after radiotherapy.

Dr. Nimer on the Biggest Challenges of MDS

May 1st 2015

Stephen D. Nimer, MD, Director, Professor of Medicine, Sylvester Comprehensive Cancer Center discusses the challenges of treating myelodysplastic syndromes (MDS).

T-Cell Depleted Allografts Lessen GVHD in MDS

May 1st 2015

Treatment with T-cell depleted transplantation was associated with a lower incidence of acute graft versus host disease (GVHD) and a very low incidence of chronic GVHD compared with unmodified allografts in patients with advanced myelodysplastic syndrome.

Lenalidomide Improves Quality of Life in Non-Del5q MDS

May 1st 2015

Treatment with lenalidomide (Revlimid) versus placebo improved health-related quality of life (HRQoL) after 24 weeks for patients with myelodysplastic syndromes.

Supportive Care Remains Backbone of Treatment in MDS

May 1st 2015

Treatment strategies for patients with myelodysplastic syndromes are built upon a foundation of supportive care, which consists of transfusions, iron chelation, and growth factor therapy.

Sara Tinsley Discusses Quality of Life in Patients with High-Risk MDS

May 1st 2015

Sara M. Tinsley, MS, PhD, ARNP, AOCN, nurse practitioner, malignant hematology, Moffitt Cancer Center, discusses a study that examined quality of life in patients with high-risk myelodysplastic syndromes (MDS).

Dr. Komrokji on Risk Stratification of Therapy-Related MDS

May 1st 2015

Rami S. Komrokji, MD, clinical director, Department of Malignant Hematology, H. Lee Moffitt Cancer Center, discusses a study that examined risk stratification of therapy-related MDS.

HLA-Matched Transplantation Improves OS in High-Risk MDS

April 30th 2015

HLA-matched allogeneic hematopoietic stem cell transplantation was associated with more than a doubling in 4-year overall survival rates for patients with intermediate-2 or high-risk myelodysplastic syndromes.